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AbstrACt
Objective Evaluate the association between gout and risk 
of advanced chronic kidney disease (CKD).
Design Retrospective matched cohort study.
setting UK Clinical Practice Research Datalink.
Participants The analysis included data for 68 897 
patients with gout and 554 964 matched patients without 
gout. Patients were aged ≥18 years, registered at UK 
practices, had ≥12 months of clinical data and had 
data linked with Hospital Episode Statistics. Patients 
were excluded for history of advanced CKD, juvenile 
gout, cancer, HIV, tumour lysis syndrome, Lesch-Nyhan 
syndrome or familial Mediterranean fever.
Primary and secondary outcome measures Advanced 
CKD was defined as first occurrence of: (1) dialysis, kidney 
transplant, diagnosis of end-stage kidney disease (ESKD) 
or stage 5 CKD (diagnostic codes in Read system or 
International Classification of Diseases, Tenth Revision); 
(2) estimated glomerular filtration rate (eGFR) <10 mL/
min/1.73 m²; (3) doubling of serum creatinine from 
baseline and (4) death associated with CKD.
results Advanced CKD incidence was higher for patients 
with gout (8.54 per 1000 patient-years; 95% CI 8.26 to 
8.83) versus without gout (4.08; 95% CI 4.00 to 4.16). 
Gout was associated with higher advanced CKD risk 
in both unadjusted analysis (HR, 2.00; 95% CI 1.92 to 
2.07) and after adjustment (HR, 1.29; 95% CI 1.23 to 
1.35). Association was strongest for ESKD (HR, 2.13; 
95% CI 1.73 to 2.61) and was present for eGFR <10 mL/
min/1.73 m² (HR, 1.45; 95% CI 1.30 to 1.61) and serum 
creatinine doubling (HR, 1.13; 95% CI 1.08 to 1.19) but 
not CKD-associated death (HR, 1.14; 95% CI 0.99 to 1.31). 
Association of gout with advanced CKD was replicated in 
propensity-score matched analysis (HR, 1.23; 95% CI 1.17 
to 1.29) and analysis limited to patients with incident gout 
(HR, 1.28; 95% CI 1.22 to 1.35).
Conclusions Gout is associated with elevated risk of CKD 
progression. Future studies should investigate whether 
controlling gout is protective and reduces CKD risk.
IntrODuCtIOn
Chronic kidney disease (CKD) is a major 
public health epidemic, with at least 1 in 10 
individuals having some degree of kidney 
impairment, contributing substantially to 
adverse clinical and economic outcomes.1–3 
While attention has traditionally focused on 
the identification and treatment of common 
CKD risk factors such as hypertension, 
diabetes and smoking, there is increasing 
interest by the scientific community in the 
role of novel risk factors, such as uric acid and 
gout, which may independently contribute 
to disease progression and higher rates of 
end-stage kidney disease (ESKD).4–6 Evidence 
has emerged that the burden of gout and 
hyperuricaemia is high in the general popu-
lation and increases with progressive CKD.7 
Importantly, a large proportion of these 
patients remain undertreated and continue 
to have uncontrolled gout.8
Gout is a common inflammatory arthritis 
caused by deposition of monosodium urate 
crystals in joints and as a consequence 
of longstanding asymptomatic hyperuri-
caemia. Despite advances in clinical care, 
gout remains poorly managed in the 
general population with only one-third of 
patients receiving treatment with urate-low-
ering therapy (ULT)9 and less than 50% of 
patients achieving gout control.10–13 Exper-
imental studies have convincingly shown 
that elevated uric acid levels initiate renal 
injury through intraglomerular hypertension 
and the development of tubulointerstitial 
fibrosis.14 15 Prospective observational studies 
have yielded strong independent associations 
strengths and limitations of this study
 ► The large sample size of more than 600 000 patients 
and moderate follow-up period provided a powerful 
mechanism to examine multiple outcomes.
 ► The study cohort analysed data from Clinical 
Practice Research Datalink, ensuring that results 
are broadly generalisable to primary care practices 
in the UK health system population.
 ► Comprehensive data on several confounders were 
accounted for in the analysis, but these did not ex-
plain the strong relationship between gout and risk 
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Figure 1 Study participant flow diagram. CKD, chronic 
kidney disease; CPRD, Clinical Practice Research Datalink; 
eGFR, estimated glomerular filtration rate; HES, Hospital 
Episode Statistics; ONS, Office for National Statistics; ULT, 
urate-lowering therapy.
between hyperuricaemia and kidney disease progression 
with elevated risks for CKD and kidney failure.16–18 It is 
plausible that gout may further increase the risk of CKD 
compared with hyperuricaemia alone, potentially medi-
ated by higher urate burden, longer periods of exposure, 
repeated cycles of systemic inflammation from gout flares 
and greater exposure to non-steroidal anti-inflammatory 
drugs (NSAIDs).19–21 A better understanding of gout and 
its potential for increasing the risk of CKD is warranted.
The primary objective of this study was to evaluate the 
association of gout with the risk of advanced CKD in the 
UK health system. Advanced CKD was defined as the need 
for long-term dialysis or kidney transplant, progression to 
a sustained estimated glomerular filtration rate (eGFR) 
<10 mL/min/1.73 m², doubling of serum creatinine from 
baseline and death associated with CKD.
MethODs
setting and study design
This matched cohort study was based in the UK health 
system, using primary care data from the UK Clinical 
Practice Research Datalink (CPRD), linked with hospital 
admission data from Hospital Episode Statistics (HES) 
and death certificate data from Office for National Statis-
tics (ONS). This study is based in part on data from the 
CPRD GOLD database, obtained under license from 
the UK Medicines and Healthcare products Regulatory 
Agency (MHRA). The data are provided by patients and 
collected by the National Health Service as part of their 
care and support (HES and ONS data, Copyright 2018, 
reused with the permission of The Health and Social Care 
Information Centre. All rights reserved). The interpreta-
tion and conclusions contained in this report are those of 
the authors alone.
Data sources
The CPRD contains anonymised information recorded 
during routine clinical practice including clinical 
diagnoses, prescriptions and laboratory data from over 
11 million patients attending 674 general practices across 
the UK.22 HES captured hospitalisation information on 
all hospitalisation episodes in England. Linked HES data 
are available for approximately 70% of CPRD practices in 
England.22 CPRD is also linked to death information from 
the ONS and provides detailed information on date and 
cause of death. The Read code system is used for coding 
diagnoses in CPRD while the International Classification 
of Diseases, Tenth Revision (ICD-10) system is used in 
HES and ONS data. Data were available until July 2015 
for CPRD, April 2014 for HES and May 2014 for ONS.
study population
The study population included adult patients in CPRD 
from 1 January 2000 to 31 March 2013 who were classified 
by the presence (exposed cohort) or absence (unexposed 
cohort) of gout. A diagnosis of gout was based on a clin-
ical record of gout or prescription of ULT in CPRD. The 
index date in the exposed group was defined as the date 
of gout diagnosis between 1 January 2000 and 31 March 
2013, based on the date of first gout disease record or the 
date of first treatment with a ULT during this period. An 
initial matching strategy was used to ensure patients were 
assessed at a similar point in time (from index date) and 
to balance demographic characteristics between gout and 
non-gout patients (ratio 1:up to 10), with matching on year 
of birth, sex, registered general practice and availability 
of data linkage with HES and ONS data. Eligible non-gout 
patients were randomly assigned (without replacement) 
to the gout patients and allocated the index date of their 
matched gout patient. Non-gout patients who developed 
incident gout during follow-up were then also assigned 
to the gout cohort (with a new index date from the gout 
diagnosis), that is, there were time-varying exposures.
Patients were included in the study if they were: aged 
≥18 years at index date, had at least 12 months of clinical 
data prior to the index date, were registered at practices 
in England and had data linked with HES. Patients were 
excluded if they had history of advanced CKD (defined 
as treatment with dialysis, recipient of kidney transplant, 
stage 5 CKD or eGFR <15 mL/min/1.73 m² on or before 
index date).23–25 Additionally, patients were excluded if 
there was a history of juvenile gout, cancer, HIV, tumour 
lysis syndrome, Lesch-Nyhan syndrome or familial Medi-
terranean fever. The flow diagram for cohort construc-
tion is shown in figure 1. There were 205 295 patients 
with gout between 1 January 2000 and 31 March 2013 
in CPRD. Of these, 112 009 met the eligibility criteria 
and were matched to 1 035 552 patients without gout, of 
whom 900 462 met eligibility criteria (figure 1). For the 
primary analysis, 68 897 patients with gout were matched 
with 554 964 patients without gout. For sensitivity anal-
yses, two additional cohorts were constructed to validate 
the results. First, we created a subgroup from the original 
gout cohort and propensity score-matched patients with 
gout (n=64 420) with those without (n=286 110). Second, 
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Figure 2 Illustration of study population selection and 
study periods. CPRD, Clinical Practice Research Datalink; 
HES, Hospital Episode Statistics; ONS, Office for National 
Statistics.
compared 53 006 patients with a new diagnosis of gout to 
432 720 patients without gout.
Follow-up data were available until the end of patient’s 
record collection, practice’s last CPRD/HES/ONS data 
availability and outcome event date or, in the case of the 
non-gout cohort, the date of onset of new gout diagnosis. 
The study population and study periods are illustrated in 
figure 2.
Primary outcome
Advanced CKD, a composite outcome, was defined as 
first occurrence of: (1) ESKD, defined as long-term dial-
ysis, kidney transplant, diagnosis of ESKD or stage 5 CKD 
(from diagnostic codes in Read system or ICD-10); (2) 
eGFR <10 mL/min/1.73 m² (from laboratory results in 
CPRD); (3) doubling of serum creatinine from baseline 
from laboratory data in CPRD and (4) death associated 
with CKD (from ONS mortality data). Deaths were deter-
mined to be associated with CKD if one or more ICD-10 
code identifying CKD was recorded in any of the cause-
of-death fields (see list of ICD-10 codes in online supple-
mentary material). An eGFR <10 mL/min/1.73 m² was 
chosen as an outcome instead of <15 mL/min/1.73 m² 
(which is a component of kidney failure according to 
Kidney Disease Improving Global Outcomes clinical 
guidelines26) to more precisely capture kidney failure. In 
the UK, most patients initiate dialysis at an eGFR <10 mL/
min/1.73 m².27 The inclusion of creatinine doubling 
captures the progression of CKD, which would have been 
excluded had outcomes been restricted to those of ESKD.
Confounders and other measured covariates
The following variables were included in our analyses: 
demographic factors (age, sex), socioeconomic status 
(Townsend score of social deprivation), comorbid condi-
tions (diabetes, hypertension, myocardial infarction, 
angina, heart failure, ischaemic heart disease, coronary 
artery disease, peripheral arterial disease, stroke, tran-
sient ischaemic attack, stage of CKD, acute kidney injury, 
peptic ulcer disease, rheumatic disease, obesity, depres-
sion, dementia) and lifestyle traits (smoking status, 
alcohol use, history of drug addiction). An age-adjusted 
Charlson Comorbidity Index was used to measure disease 
severity.28 Data on nephrotoxic medications, NSAIDs and 
drugs that alter serum creatinine levels (ACE inhibitors, 
angiotensin-receptor blockers (ARB), diuretics, corti-
costeroids, aspirin) were also considered as potential 
confounders in exposure–outcomes relationship. Serum 
creatinine values were used to estimate kidney function 
through calculation of eGFR using the Chronic Kidney 
Disease Epidemiology Collaborative equation.23–25 Data 
on all patient characteristics were captured during any 
time prior to index date and were considered for inclu-
sion in the multivariable models for adjustment.
statistical methods
Incidence rates expressed as events divided by patient-
years were calculated for advanced CKD and its four 
components and reported per 1000 patient-years. 
Univariable and multivariable marginal Cox proportional 
hazards models were developed to estimate unadjusted 
and adjusted HRs and 95% CIs of advanced CKD associ-
ated with gout. Models accounted for the matched cohorts 
(therefore differences in age, sex, registered clinical 
practice, number of matched controls) and intracluster 
dependence introduced by patients who developed inci-
dent gout over time and subsequently reclassified from 
the non-gout to the gout cohort (ie, time-varying expo-
sures). The models of each component of the primary 
outcome also accounted for the competing risk of the 
other components. Adjusted models accounted for base-
line differences in patient characteristics including prev-
alent comorbid conditions, social deprivation status, 
lifestyle traits, clinical measurements and prescribed 
medications (ACE, ARB, NSAIDs, corticosteroids, thia-
zide diuretics and aspirin). A manual backwards selection 
approach with a 5% significance level was used in model 
development. Model assumptions were assessed using 
standard residual-based procedures, and potential collin-
earity between covariates was investigated (all covariates 
had a variance inflation factor <4 and were therefore 
retained in the model). Subgroups of clinically important 
characteristics were explored to determine whether they 
altered the association between gout and advanced CKD. 
The following characteristics were selected a priori as clin-
ically important: diabetes, heart failure and CKD stage. 
Stratum-specific HRs of advanced CKD were computed 
for each subgroup for patients with and without gout. No 
imputation was performed on missing clinical values; the 
extent of missing values was presented in descriptive anal-
yses and then excluded from the statistical models. All 
statistical analyses were conducted using SAS V.9.4.
sensitivity analyses
Several sensitivity analyses were conducted to evaluate the 
robustness of our findings. First, to exclude potential bias 
associated with a diagnosis of prevalent gout (included in 
gout cohort with a history of gout), we restricted the study 
cohort to patients who developed incident gout (ie, index 
date was their first ever record of gout) and repeated the 
entire analysis. Second, the association between gout 
and advanced CKD was explored in a propensity-score 
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between groups and reduce selection bias. Patients with 
gout were matched with up to five patients without gout 
based on their probability of being assigned to the gout 
cohort using propensity scores derived from a logistic 
regression model using a nearest neighbour matching 
with a calliper of 0.2.
Patient and public involvement
We did not involve patients or the public in our work.
results
Patient characteristics
The study cohort included 623 861 patients with and 
without gout followed for a median of 3.68 years (see 
online supplementary table 1). The prevalence of 
known risk factors for kidney disease, including hyper-
tension, diabetes, hyperlipidaemia, ischaemic heart 
disease, benign prostatic hyperplasia, pre-existing CKD 
and history of acute kidney injury, was more common in 
patients with gout than without. Moreover, these patients 
were more often prescribed reno-protective medications, 
diuretics and NSAIDs. While patients were matched on 
year of birth and sex, the gout cohort was marginally older 
overall than the non-gout cohort (median age 62 and 59 
years, respectively) as older patients with gout tended to 
have fewer patients without gout available for matching 
(see online supplementary table 1). The overall propor-
tion of men was similar between cohorts (76.7% among 
gout cohort, 77.1% among non-gout cohort). Distribu-
tion of baseline characteristics was similar between the 
623 861 patients with gout and without included in the 
final study population and the 1 012 471 patients with 
gout and without in the original cohort who met eligi-
bility criteria but had no linked HES or ONS data avail-
able (see online supplementary table 2).
risk of advanced CKD
During 3.7 years of median follow-up (IQR, 1.7–7.0) there 
were 3452 incident CKD events among 404 035 patient-
years in the gout cohort and 10 187 incident events 
among 2 498 498 patient-years in the cohort without gout 
(table 1). The unadjusted analysis found that patients 
with gout experienced 2.00 (95% CI 1.92 to 2.07) times 
the risk of advanced CKD relative to those without gout 
(table 1 and illustrated in figure 3). With adjustment 
for potential confounders, the risk was attenuated but 
remained statistically significant (HR, 1.29; 95% CI 1.23 
to 1.35, p<0.001).
For each component of the primary outcome, incidence 
rates of CKD were consistently higher among patients 
with gout compared with those without gout although 
the magnitude of the associations varied (table 1). For 
the outcome of ESKD, the greatest magnitude of associ-
ation was observed with patients with gout having 2.13 
(95% CI 1.73 to 2.61) times the risk of incident ESKD 
compared with patients without gout following adjust-
ment. The pattern was similar for other component parts 
of the composite outcome (eGFR <10 mL/min/1.73 m² 
(HR, 1.45; 95% CI 1.30 to 1.61) and doubling of serum 
creatinine (HR, 1.13; 95% CI 1.08 to 1.19), although the 
magnitude of the relationship was less. The association 
of gout with death associated with CKD did not achieve 
statistical significance (HR, 1.14; 95% CI 0.99 to 1.31).
sensitivity analyses
Sensitivity analyses yielded associations between gout 
and advanced CKD that were similar to the main anal-
ysis; adjusted HR 1.28 (95% CI 1.22 to 1.35) for inci-
dent patients with gout compared with matched patients 
without gouts and 1.23 (95% CI 1.17 to 1.29) among 
propensity score-matched patients with gout and without 
(see online supplementary figure 1).
subgroup analyses
The association of gout and advanced CKD varied when 
stratified by the presence or absence of comorbidities 
(figure 4). While the level of statistical evidence varied, 
overall the gout cohort had higher risk of advanced CKD 
than the non-gout cohort across all groups with and 
without history of CKD (no CKD: HR, 1.46; 95% CI 1.31 
to 1.64; early-stage CKD: HR, 1.07; 95% CI 0.96 to 1.19; 
moderate-stage CKD: HR, 1.18; 95% CI 1.06 to 1.31). The 
highest risk was observed among patients with history of 
heart failure (HR, 1.84; 95% CI 1.00 to 3.38), although 
the CI was wide, followed by those without the underlying 
condition (HR, 1.21; 95% CI 1.14 to 1.28). There was no 
evidence of an association between gout and advanced 
CKD among patients with a history of diabetes (HR, 
0.96; 95% CI 0.77 to 1.19); however, patients with gout 
but without diabetes had higher risk of advanced CKD 
compared with patients without gout (HR, 1.31; 95% CI 
1.24 to 1.40).
DIsCussIOn
This large observational study provides strong evidence of 
an association between gout and progression to advanced 
CKD in the real-world setting of routine clinical prac-
tice in the UK health system between January 2000 and 
July 2015. After accounting for differences between the 
two cohorts, patients with gout had a 29% higher risk 
of advanced CKD than patients without gout (HR, 1.29, 
95% CI 1.23 to 1.35). These findings were consistent in 
sensitivity analyses conducted among patients newly diag-
nosed with gout (HR, 1.28; 95% CI 1.22 to 1.35) and 
among a propensity score-matched subpopulation (HR, 
1.23; 95% CI 1.17 to 1.29). Of the four components of 
the primary outcome, the highest risk was observed for 
ESKD (HR, 2.13; 95% CI 1.73 to 2.61). The risk was also 
present for several surrogate measures of CKD progres-
sion including a doubling of serum creatinine and 
progression to a GFR value <10 mL/min/1.73 m². The 
association remained when stratified by the presence or 
absence of early-stage CKD and heart failure, although 
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Figure 3 Cumulative probability of advanced chronic kidney 
disease among patients with and without gout. CKD, chronic 
kidney disease.
Figure 4 Adjusted HR for the risk of advanced chronic 
kidney disease for patients with gout versus without 
among subgroups with history of comorbidities, which 
were identified a priori as clinically important patient 
characteristics.
This is perhaps due to the high risk of ESKD caused by 
nephropathy in patients with diabetes29 outweighing the 
risk caused by gout.
Although it is known that the presence of CKD contrib-
utes to the progression of hyperuricaemia and gout, the 
findings from this national observational cohort study of 
patients in the UK health system demonstrate that gout is 
also strongly associated with an increased risk of advanced 
CKD. After adjusting for known confounders, the associ-
ation of gout with advanced CKD was not explained by 
differences in demographic or socioeconomic factors, 
the presence or severity of prevalent comorbid condi-
tions including pre-existing CKD or the use of known 
nephrotoxic medications. The magnitude of the gout–
CKD association was greatest for a diagnosis of ESKD with 
over a twofold higher risk, but the risk was also present 
for several surrogate measures of CKD progression, 
including a doubling of serum creatinine and progression 
to an eGFR value <10 mL/min/1.73 m². These findings 
were confirmed in propensity-matched analysis and were 
further validated in sensitivity analysis where we included 
only patients with incident gout. Taken together, these 
observations suggest that gout is an independent risk 
factor for progression to advanced CKD.
This study sheds new light on the pattern and magni-
tude of association of gout with the risk of CKD in the 
general population. While previous observational studies 
have convincingly shown that patients with gout have a 
high burden of CKD, and risk factors for CKD compared 
with those without gout,30 31 only one study to our knowl-
edge has explored the direct impact of gout on the future 
risk of advanced CKD. Yu et al using data from the National 
Taiwanese Health System, found that gout was associ-
ated with a 57% higher hazard of ESKD compared with 
patients without gout adjusting only for age, sex, diabetes 
and hypertension; the failure to account for common 
kidney disease risk factors including nephrotoxic medica-
tions was a notable limitation.32 In the current analysis, we 
carefully considered several known CKD risk factors that 
could confound the association of gout with advanced 
CKD.33 Each multivariable model adjusted for a compre-
hensive set of explanatory sociodemographic charac-
teristics, kidney-specific factors including nephrotoxic 
medications and lifestyle factors known to be related to 
CKD. Yet when we accounted for these factors in adjusted 
analyses, the pattern of association of gout with advanced 
CKD remained.
Our analysis suggests a strong relationship between 
clinical gout, an index of cumulative burden of hyper-
uricaemia and the risk of progressive CKD. It extends an 
emerging body of evidence that supports a role for chronic 
hyperuricaemia in the pathogenesis of CKD.34 Exper-
imental studies in animals have demonstrated biolog-
ical plausibility from uric acid-induced intraglomerular 
hypertension and tubulointerstitial fibrosis.14 15 Obser-
vational studies in humans have yielded strong indepen-
dent associations between hyperuricaemia and hazards of 
CKD progression including ESKD.35–37 Further support 
of a possible causal relationship stems from quasiran-
domised studies and clinical trials that suggest a slowing 
of CKD progression with ULTs38 39 and prevention of 
ESKD,18 although these findings require confirmation in 
large clinical trials.40–42
This study is not without limitations. The case defini-
tion of gout was based on both physician diagnosis and 
treatment with ULT rather than on strict clinical and 
laboratory criteria alone. While we recognise the poten-
tial for misclassification, previous studies have shown that 
this definition has high validity.32 Moreover, the complete-
ness and accuracy of CPRD data has been confirmed 
with Read code diagnoses of gout having a 90% positive 
predictive value.43 44 Even with this broad definition, it is 
possible that some cases of gout, where poorly recorded 
or underdiagnosed in the population, would not have 
been captured. We also submit that variation may exist in 
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test results between practitioners, primary care prac-
tices and over time. This was mitigated through the use 
of HES-linked data to identify secondary care diagnoses 
and the 2004 introduction of the Quality and Outcomes 
Framework that incentivised practices to improve elec-
tronic recording.22 As with all observational studies, we 
acknowledge the possibility of residual confounding 
due to unmeasured characteristics, however, the CPRD 
captured data on multiple confounders including prev-
alent comorbid conditions, severity of illness indicators, 
kidney-specific risk factors, lifestyle traits and socioeco-
nomic factors, which allowed us to examine in detail 
the independence of the gout–CKD relationship. The 
availability of data on these factors is potentially subject 
to selection bias, as patients with gout or CKD would 
be more likely to interact with the healthcare system. A 
further source of selection bias could be the exclusion of 
patients, although the majority of exclusions were unre-
lated to patient characteristics such as the availability of at 
least 12 months of historical data and data linkage.
The limitations of this study were counterbalanced by 
several strengths. The large sample size of over 600 000 
patients and moderate period of follow-up provided a 
powerful mechanism to examine multiple outcomes 
including ESKD. The study cohort analysed data from 
CPRD,22 ensuring that our results are broadly generalis-
able to primary care practices in the UK health system 
population. The availability of detailed data on common 
kidney disease risk factors including nephrotoxic medi-
cations provided us with an additional opportunity to 
account for the influence of these factors in the gout–
CKD relationship. Recognising that patients with gout 
had higher burden of comorbid disease and risk factors, 
we adjusted for an extensive set of baseline characteristics 
in the primary analysis, conducted additional propensity 
score sensitivity analysis and repeated the entire analysis 
in patients exposed to incident gout. In each of these anal-
yses, the independent association of gout with advanced 
CKD was confirmed following covariate adjustment.
We conclude that gout is independently associated with 
the risk of advanced CKD in the UK health system. The 
risk was greatest for the outcome of ESKD but extended 
to other surrogate measures of CKD progression. This 
relationship was not explained by prevailing burden of 
medical conditions, lifestyle factors, NSAID use or differ-
ences in socioeconomic factors measured at baseline. The 
overall findings add to the accumulating body of evidence 
that gout is an independent risk factor for kidney disease 
progression, although further work is needed to establish 
whether adequate control of gout can reduce the risk of 
CKD progression.
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